Treatment of mild and moderate hypertension with enalapril (multicenter study of enap and enap N in Ukraine)
Dziak, G.V.; Kolomiets, S.N.; Minakov, A.I.; Fushteĭ, I.M.; Iavorskiĭ, O.G.; Bekker, V.F.; Vankhanen, V.N.; Davydova, I.V.; Zaĭtseva, V.I.; Kolesnik, T.V.; Kolomiets, V.V.; Svishchenko, E.P.; Taran, A.I.; Shlykova, N.A.; Barbich-Zhagar, B.
Terapevticheskii Arkhiv 71(1): 31-34
1999
ISSN/ISBN: 0040-3660 PMID: 10097297 Document Number: 508657
Assessment of efficiency and safety of enalapril (enap) and its combination with hydrochlorotiaside (enap-N). 127 patients with mild and moderate blood hypertension entered an open non-comparative multicenter trial. 60 of them received enap (group 1), 67--enap N (group 2). Group 1 patients were given enap for 2 weeks in a dose 10 mg/day. If this dose was not adequate to normalize blood pressure, it was raised to 20-40 mg/day. Patients of group 2 received enap-N one tablet a day for 3 weeks. If the pressure persisted higher than 140/90 mm Hg, the treatment was continued for 3 weeks more in a dose of 2 tablets a day. Blood pressure lowered under 140/90 mm Hg in 40 patients of group 1 (66.7%). Systolic pressure dropped by 10 mm Hg minimum and diastolic by 5 mm minimum in 18 group 1 patients (30%). Enap-N reduced blood pressure under 140-90 mm Hg in 44 of 67 patients (65.7%). Systolic and diastolic pressure dropped, respectively, in 23(34.3%) patients. Enap and enap-N tablets were found highly effective and well tolerated. Side effects were caused by lowering of blood pressure.